The abstract is read at the publisher; the summary is JClub's.
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, based on the phase III evERA trial results.
- Why it matters: Treatment selection for ER-positive, HER2-negative disease depends on identifying ESR1 mutations, and the approval addresses a need for an effective targeted regimen.
- What they did: The phase III evERA trial evaluated giredestrant in combination with everolimus, and the FDA also authorized FoundationOne Liquid CDx to assess ESR1 status.
- The result: The approval enables use of this regimen for patients with ESR1-mutated tumors, using FoundationOne Liquid CDx to guide eligibility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.